
Lost underwater forests are returning to Sydney's coastline
Crayweed, a large, golden-brown seaweed, found along Australia's southeastern coast, plays a crucial role in ocean health. Its underwater forests capture carbon, create shelter for marine species and serve as a nursery for creatures like abalone and rock lobsters.
Once widespread along Sydney's coastline, it disappeared from a 70-kilometer stretch around the 1980s, at a time when sewage was being discharged into the sea, according to Operation Crayweed. The conservation initiative, primarily run by scientists from universities and research institutes, aims to restore 60 hectares of forest in shallow rocky reef habitats.
'We're not just bringing back one species, we're building an entire ecosystem,' says Dr. Adriana Vergés, a professor of marine ecology at the University of New South Wales Sydney, and co-founder of Operation Crayweed.
Improvements in sewage disposal mean the water around Sydney has become clean enough to support crayweed, according to the group, but for it to make a return, it must first be planted and then successfully reproduce.
At designated restoration sites, scientists and volunteers attach healthy male and female crayweed collected from wild populations onto biodegradable mats fixed to reefs.
Crayweed reproduces when male plants release sperm into the water, which fertilizes eggs from the female plant. These fertilized eggs grow into young crayweed, known as 'craybies,' which anchor to the seafloor and grow into new forests.
Once established, the mats are removed, and the forest continues to grow and spread on its own.
Since Operation Crayweed began over a decade ago, it has targeted 16 sites along Sydney's reefs, seven of which now have established self-sustaining crayweed populations. The restored forests cover over two hectares, and microscopic animals are already returning, according to Vergés.
Three new sites, Lurline Bay, Dee Why, and South Maroubra, were added in 2024. Dee Why alone jumped from just 10 crayweed plants to 466 juvenile crayweed in a single year and by early 2025, more than 1,500 craybies had established themselves at South Maroubra, according to Operation Crayweed.
'I get a real kick out of seeing it. And now it's expanded so much that you can see it even without getting in the water,' says Vergés. 'When the tide is low, you can see the crayweed swaying as the water pulls away from the coast.'
The team plans to restore 10 more sites in the next two and a half years.
Dr. Prue Francis, a senior lecturer in marine science at Deakin University, who isn't part of Operation Crayweed, says the project can have a wider impact in the area.
'People often focus on the dramatic bleaching of coral reefs, but with kelp forests, the decline is quieter, until it's too late. These underwater forests are supporting a whole ecosystem. When they're gone, like in parts of Sydney where crayweed has vanished, nothing grows back,' she told CNN.
'Restoration efforts like Operation Crayweed aren't just about bringing back seaweed, they're about saving an entire web of life that depends on it,' she added.
As well as planting crayweed, the team is using advanced techniques to help it survive in a world where climate change is making oceans warmer, and environmental conditions more extreme.
It has successfully mixed genetic populations sourced from north and south of Sydney, which enables the restored populations to reflect the natural genetic diversity and structure of healthy existing populations — 'an important innovation,' says Vergés — and is testing whether crayweed genetics or its microbes (tiny living organisms that live on its surface) play a greater role in helping it survive rising ocean temperatures.
The team is also looking to build up a 'biobank' of crayweed populations as a contingency in case they are wiped out by a heatwave.
'In Western Australia, such a marine heatwave erased entire crayweed populations. To prevent similar losses, we are turning to cryopreservation,' says Vergés. 'We collect the sperm and eggs from different populations and freeze them at ultra-low temperatures.'
While other kelp species have been cryopreserved in research labs around the world, no one had successfully applied the method to crayweed, says Catalina López-Bermúdez, who is working on freezing efforts as part of her PhD at the University of Sydney.
'We don't have any genotypes or biobanks for these species,' she explained. 'So, if we lose a population, it's gone forever.'
Beyond the technical challenge, the work has a deeper meaning for López-Bermúdez: 'Sometimes, as a young scientist, it's hard not to feel hopeless. But this feels like something real, something that can make a difference,' she says. 'It gives you hope.'
The efforts of Operation Crayweed are part of wider global efforts to recover lost kelp habitat. The Kelp Forest Challenge aims to restore four million hectares of kelp globally by 2040.
For Vergés, the success of the project is both scientific and personal. 'I swim in the ocean on weekends, and everywhere I go now, I see crayweed again,' 'she says. 'It was gone, and it never would've come back by itself.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
an hour ago
- Associated Press
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for accelerated approval of TXM for bird flu Phase 2 study protocol submitted to HREC to evaluate ratutrelvir in newly diagnosed COVID patients, with extensions to measure disease rebound and development of Long COVID NEWTOWN, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ('Traws Pharma', 'Traws' or 'the Company'), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced multiple regulatory submissions related to its antiviral pipeline. Tivoxavir marboxil A proposed Phase 2 dose-ranging, non-inferiority study will evaluate the effects of tivoxavir marboxil (TXM), a potential best in class CAP-dependent endonuclease inhibitor, compared to XOFLUZA®, in patients infected with seasonal influenza. A separate single arm will evaluate the effects of TXM in patients infected with H5N1 bird flu. The proposed study has been submitted for Human Research Ethics Committee (HREC) review and is expected to enroll subjects in Australia and selected countries in Southeast Asia (SE Asia) with high rates of human bird flu infections. 'This combined study, evaluating the effects of TXM in seasonal and bird flu patients, could support the broad use of TXM against multiple influenza strains,' commented Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention (CDC). 'The high rates of animal-to-human transmission of bird flu in SE Asia should allow us to evaluate the efficacy of TXM in this important clinical setting, adding to our robust pre-clinical efficacy results of TXM against bird flu.' Also, as a follow up to recent Pre-IND FDA interactions on TXM, Traws submitted briefing materials for a Type D meeting to enable further FDA dialog on a potential path to accelerated approval for bird flu. 'We are continuing to discuss with the FDA the applicability of the Animal Rule and other routes that could support an accelerated approval of TXM for bird flu,' commented C. David Pauza, PhD, Chief Science Officer for Traws Pharma. 'We look forward to continuing positive interactions with the Agency.' Ratutrelvir A proposed Phase 2 non-inferiority study will evaluate the effects of ratutrelvir, a potential best in class protease inhibitor that does not require ritonavir co-administration, compared to PAXLOVID®, in newly diagnosed COVID patients. The proposed study that has been submitted for HREC review is intended to enroll patients on a 10-day treatment regimen for ratutrelvir compared to the approved 5-day regimen for PAXLOVID®. In addition to efficacy and safety endpoints, the proposed study will also evaluate the rates of disease rebound as well as the incidence of Long COVID. A separate single arm will evaluate the safety and efficacy of ratutrelvir in newly diagnosed COVID patients who are ineligible for treatment with PAXLOVID®. 'A significant population of patients who are at risk for poor outcomes from COVID are ineligible for PAXLOVID®. In addition, rebound infections and prevention of the development of Long COVID are unaddressed by existing therapies. We believe ratutrelvir has the potential to overcome these issues,' commented Dr. Redfield. 'Our proposed Phase 2 study is expected to highlight the differentiating attributes of ratutrelvir compared to existing approved therapies.' 'Today's announcements demonstrate our commitment to rapidly advance our antiviral portfolio,' commented Iain D. Dukes, MA, DPhil, Interim Chief Executive Officer for Traws Pharma. 'We look forward to delivering these potentially vital medicines to patients.' About Tivoxavir Marboxil Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza. It has potent in vitro activity against a range of influenza strains in preclinical studies, including a human isolate of the highly pathogenic avian flu H5N1 (bird flu). Consistent, positive preclinical data from three animal species indicate that a single dose of TXM demonstrated a therapeutic effect against H5N1 bird flu. Seasonal influenza represents an estimated multi-billion dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders1,2, with upside potential from potential pandemic flu outbreaks including H5N1 bird flu. We believe that these data support further development of TXM as a treatment for bird flu. About Ratutrelvir Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to be a broadly acting treatment for COVID-19 that is used without ritonavir. It has demonstrated in vitro activity against a range of COVID-19 strains. Preclinical and Phase 1 studies show that ratutrelvir does not require co-administration with a metabolic inhibitor, such as ritonavir, which could avoid ritonavir-associated drug-drug interactions3, and potentially enable wider patient use. Phase 1 data also show that ratutrelvir's pharmacokinetic (PK) profile demonstrated maintenance of target blood plasma levels approximately 13 times above the EC50 using the target Phase 2 dosing regimen of 600 mg/day for ten days, which may also reduce the likelihood of clinical rebound and, consequently, reduce the risk for Long COVID4. Industry data indicate that COVID treatment represents a potential multi-billion dollar market opportunity5,6. Source information: Third-party products mentioned herein are the trademarks of their respective owners. About Traws Pharma, Inc. Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease). Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws' website at For more information, please visit and follow us on LinkedIn. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, benefits and the regulatory plans for tivoxavir marboxil. The Company has attempted to identify forward-looking statements by terminology including 'believes', 'estimates', 'anticipates', 'expects', 'plans', 'intends', 'may', 'could', 'might', 'will', 'should', 'preliminary', 'encouraging', 'approximately' or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including our ability to proceed with our proposed clinical trials and to enroll sufficient subjects in such studies and trials, the success and timing of Traws' clinical trials, our ability to take advantage of expedited regulatory pathways for tivoxavir marboxil, our ability to obtain regulatory approval of tivoxavir marboxil and ratutrelvir, the expectations of our interactions with regulatory authorities, including the FDA, the Human Research Ethics Committee (HREC) and other international regulatory agencies, market conditions, regulatory requirements, changes in government regulation, the extent of the spread and threat of bird flu, seasonal influenza and COVID, and those discussed under the heading 'Risk Factors' in Traws' filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law. Traws Pharma Contact: Nora Brennan Traws Pharma, Inc. [email protected] Investor Contact: John Fraunces LifeSci Advisors, LLC 917-355-2395 [email protected]
Yahoo
5 hours ago
- Yahoo
Scientists Detect Radio Burst From Deepest Space, Then Realize It's Just A Satellite, Then Realize The Satellite Was Signaling From Beyond The Grave
A scientific paper was recently published on Cornell University's arXiv describing a radio burst that lasted for a mere 30 nanoseconds. Maybe that doesn't sound too exciting, except that the signal was thought to come from another galaxy. But then it turned out it was just from a satellite. But then it turned out that the satellite had been dead for decades and couldn't actually produce a transmission like that. So now it's a story about a zombie satellite sending impossible messages from beyond the grave, in space. Interested yet? In June 2024, the Australian Square Kilometre Array Pathfinder (ASKAP) radio telescope detected what was thought to be a fast radio burst (FRB). Makes sense, as that was exactly what the telescope was trying to find. From reporting by FRBs remain something of a mystery even 20 years after their discovery, which of course just make scientists want to study them more. So detecting one was pretty great... until the team examining the find realized that the FRB made no sense at all. For one thing, the signal was too short — FRBs typically last micro- or milliseconds, not mere nanoseconds. Yes, those time frames are all incredibly small, but they are orders of magnitude apart. The radio telescope's image of it was also very fuzzy, which, like with a normal camera, indicated that the source was actually very, very close, not in a distant galaxy, where other FRB signals were from. What on Earth (or off it) was going on? Well, the answer turned out to be very boring, right before it got incredibly weird. Read more: These Cars Are Going To Age Terribly Once scientists had worked out the exact origin position of the signal, they realized that it was actually so close to Earth that it might well be a satellite, per New Scientist. They cross-referenced with known orbits, and sure enough, one popped up. Ah, darn, just a satellite then. No big deal — hey wait, is that satellite dead? Yes, and not just dead, but long dead. NASA's Relay 2 was in fact one of the first ever satellites, launched all the way back in 1964 at the dawn of the space age. Along with its sister Relay 1, these were experimental communications satellites intended to map the Van Allen radiation belt, per our friends at Gizmodo. Then in June 1967 (everything in this story happens in June, weird), the transponders failed, and that was the end of that. Except, now it isn't. Apparently the long-dead experimental communications satellite decided to get very experimental with its communications, since it sent out a radio burst all of a sudden. If you're wondering how a dead satellite can do that, you're not alone, because no one knows for sure. In fact, the on-board equipment is not even capable of transmitting a 30 nanosecond pulse. Rising from the grave to send impossible messages? What is this, space Ouija? In their scientific paper, the team theorizes one of two possible explanations, as lays out. First is that an electrostatic discharge (ESD) might have built up, causing a brief spark that caused a radio burst. Think of rubbing your hand along a carpet, then touching something metal. In space, the "carpet" would be ionized gas or plasma, so if Relay 2 passed through some of that, it might have sparked. This has actually been observed before, but again, at much longer timescales than 30 nanoseconds, which might count against this theory. If it does prove to be true, it actually has some practical value. ESDs are known to cause damage to satellites, but they are difficult to detect. Possibly, these scientists have stumbled on a way to detect them, making it easier to diagnose a faulty satellite. The second theory, as if this all couldn't get any better, was that the zombie satellite was actually hit by a teeny tiny micrometeorite traveling at 44,000 mph. This little hypothetical guy would only be a few micrograms, but if it struck Relay 2, it would create a puff of charged plasma, which is what the radio telescope would have detected. Both of these are still just theories, and really, nobody knows for sure. If you think that space necromancers must surely be involved, I wouldn't doubt it. It all just goes to show that space is a vast, weird place, and even our brightest minds are still only just scratching the surface of all it has to tell us. Want more like this? Join the Jalopnik newsletter to get the latest auto news sent straight to your inbox... Read the original article on Jalopnik.
Yahoo
5 hours ago
- Yahoo
Scientists Investigate What Happens If You Snort Moon Dust
Wondering whether snorting Moon dust will kill you? Don't worry: science is on it. A recent study conducted by a team of Australian researchers and published in the journal Life Sciences in Space Research found that lunar dust is probably way less dangerous than space science previously feared — and, actually, might be less dangerous for humans than Earthborne air pollution. (Or, if you will: Earth dust.) For the study, the scientists focused on fine dust particles, or specks of dust that are tiny enough to tunnel far into the lungs. Using state-of-the-art simulations of lunar dust and testing those fabrications on human lungs, researchers determined that, like any dust, the lunar stuff can be irritating, but it doesn't put astronauts at risk of long-term oxidative stress or inflammation akin to what we might see from toxic air pollutants here on Earth. "Our findings suggest that while lunar dust may cause some immediate irritation to the airways, it does not appear to pose a risk for chronic, long-term diseases like silicosis, which is caused by materials like silica dust," Michaela Smith, a graduate student at the University of Technology Sydney (UTS) and the study's lead author, said in a statement. The research has been billed as a relief for the astronauts and researchers embarking — maybe? — on NASA's Artemis missions, which seek to establish a long-term human presence on the Moon. Which, of course, is already a difficult assignment, given that the Moon isn't naturally hospitable for human life (with the no-oxygen thing and everything.) If Moon dust — which is, uh, basically the whole lunar surface — were indeed toxic, that would be a seriously tricky hurdle for scientists to climb. "The results," study coauthor and UTS scientist Brian Oliver said in a statement, "contribute to the safety case for returning humans to the Moon." As for the question of whether actually snorting Moon dust Jordan Belfort-style would be a sound idea, the researchers say you probably could. But while it's unlikely you'd experience long-term illness as a result, you should be prepared for discomfort. "Any dust, if you inhale it, you'll sneeze, cough, and have some physical irritation," Smith's statement continued. "But it's not highly toxic like silica, where you end up with silicosis from being on a construction site for 10 years. It's not going to be something like that." As the adage goes: just because you can, doesn't mean you should. More on the Moon: Scientists Investigating Small Orange Objects Coating Surface of the Moon